Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1356960

USP

Leflunomide

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C12H9F3N2O2
Número de CAS:
75706-12-6
Peso molecular:
270.21
Número MDL:
MFCD00867593
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750235
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

leflunomide

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

Clave InChI

VHOGYURTWQBHIL-UHFFFAOYSA-N

Información sobre el gen

human ... DHODH(1723)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Leflunomide is a drug with cytotoxic properties. It is generally used as an immunosuppressive agent.

Aplicación

Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000654

Leflunomide, European Pharmacopoeia (EP) Reference Standard

Y0000674

Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000487

Leflunomide impurity A, European Pharmacopoeia (EP) Reference Standard

1357045

Leflunomide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1357056

Leflunomide Related Compound B, United States Pharmacopeia (USP) Reference Standard

1357067

Leflunomide Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1568

Leflunomide Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1233

Leflunomide, British Pharmacopoeia (BP) Reference Standard

PHR2878

Leflunomide Related Compound B, pharmaceutical secondary standard, certified reference material

Pictogramas

Skull and crossbones
GHS06

Palabra de señalización

Danger

Frases de peligro

H301,H315,H319,H335

Clasificaciones de peligro

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Órganos de actuación

Respiratory system

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 3

1 of 3

Teriflunomide ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomide

Cefapirin sodium salt United States Pharmacopeia (USP) Reference Standard

USP

1102500

Cefapirin sodium salt

4-(Trifluoromethyl)aniline 99%

Sigma-Aldrich

224936

4-(Trifluoromethyl)aniline

Robert P Baughman et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)
Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients
S Greene et al.
Biochemical pharmacology, 50(6), 861-867 (1995-09-07)
Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with
W James Chon et al.
Expert review of clinical immunology, 7(3), 273-281 (2011-05-21)
Leflunomide is a synthetic isoxazole-derivative drug that possesses both immunosuppressive and antiviral properties. Although its only US FDA-approved indication is for the treatment of rheumatoid arthritis, accumulating clinical experience in addition to animal study data makes it an appealing option
Frank Behrens et al.
Current opinion in rheumatology, 23(3), 282-287 (2011-03-24)
Leflunomide is often used as a first choice disease-modifying antirheumatic drug after methotrexate. New data are available for efficacy and safety in both, monotherapy and combination with biologicals. New data on efficacy demonstrate comparable effect sizes for leflunomide and methotrexate
Shigeko Inokuma
Expert opinion on drug safety, 10(4), 603-611 (2011-03-18)
Although disease-modifying antirheumatic drugs (DMARDs) are crucial for rheumatoid arthritis (RA) therapy, they have severe adverse events including interstitial pneumonitis (IP). DMARD-induced IP attracts attention because of its relatively high prevalence, occasionally fatal outcome and clinical features which are common
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico